LifeTech Scientific (HKG:1302) said Ankura Aortic Stent Graft System received official registration approval
from the China National Medical Products Administration (NMPA), according to a Wednesday filing with the Hong Kong bourse.
The system was jointly developed by Professor Shu Chang of Fuwai Hospital, Chinese Academy of Medical Sciences, and the Group. The system is an aortic stent graft system designed for the chimney technique, offering an effective treatment for aortic arch lesions with broad anatomical compatibility.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.